ea0026p245 | Pituitary | ECE2011
O'Connor R D
, van der Lely A J
, Madsen M
, Jorgenson J O
, Neggers S J C M M
Introduction: Daily administration of Pegvisomant normalizes IGF1 levels >71% of acromegalics (1). Few studies have assessed the efficacy of weekly administration. We assessed the efficacy of weekly pegvisomant for 12 months, after withdrawal of long-acting somatostatin analogs (SSA) in acromegalics previously controlled on combination therapy.Design: Fifteen subjects (8 males), age 58 (3580) (median (range)) years on combination therapy of hig...